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INTRODUCTION
Bioavailability is one of the important pharmacokinetic 
properties of drugs which are used to describe the 
fraction of an administered dose of unchanged drug 
that reaches the systemic circulation. When a drug is 
administered intravenously, its bioavailability is 100%. 
However, if the drug is administered through other 
routes (such as oral), its bioavailability decreases 
because of incomplete absorption or first pass 
metabolism. The measurement of the amount of the 
drug in the plasma at fixed time intervals indirectly 
represents the rate and extent at which the active drug 
moiety is absorbed from the drug product and becomes 
available at the site of action. Bioavailability is an 
essential tool in pharmacokinetics, which is used for 
calculating dosages for non intravenous routes of 
administration. It is expressed as either absolute or 
relative bioavailability.
1 
The   therapeutic    efficacy of   a   drug depends 
upon the ability of the dosage form to deliver the 
active drug to the site of action at a rate and amount 
which is sufficient to show the desired 
pharmacological response. This property of the dosage 
form is referred to as physiologic availability, biologic 
availability or simply bioavailability.  For almost all 
drugs, the pharmacologic response can be related 
directly to the plasma levels.  The term bioavailability 
is defined as the rate and extent (amount) of 
absorption of unchanged drug from its dosage form. 
It can also be defined as the rate and the extent to 
which the ingredients or active   moiety   is   absorbed   
from   the   drug product and becomes available at 
the site of action. A drug with poor bioavailability 
is one which has poor aqueous solubility, slow 
dissolution rate in biological fluids, poor stability of 
dissolved drug at physiological pH, poor permeation 
through biological membrane, extensive pre systemic 
metabolism. Bioavailability of poorly water soluble 
drugs is a major problem. 
Oral route is the most suitable and commonly used 
r o u t e  of drug delivery due to its ease of 
administration, high patient compliance, cost-
effectiveness, no sterility issues   and   flexibility   in   
the   design   of dosage form.  
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ABSTRACT:  
Bioavailability is defined as the rate and extent (amount) of absorption of unchanged drug from its dosage form. It is one of 
the important parameters which are required to achieve optimal concentration of drug in systemic circulation to show a 
pharmacological response. A drug which has poor bioavailability shows poor aqueous solubility, slow dissolution rate, poor 
stability of dissolved drug at physiological pH, poor permeation through biological membrane, extensive first pass 
metabolism. Drugs which are poorly water soluble require high doses to obtain therapeutic plasma concentrations after oral 
administration of drugs. Low aqueous solubility is the major problem encountered with formulation development of new 
drugs. Any drug to be absorbed must be present in the form of an aqueous solution at the site of absorption. This review 
deals with various techniques used for the improvement of the Bioavailability of drugs. The various techniques used are size 
reduction, solubilising excipients, colloidal drug delivery systems, pH adjustment, solid dispersion, complexation, 
co‐solvency, micellar solubilisation, hydrotropy etc. The article describes about various techniques which can be utilized to 
enhance bioavailability of drugs enhancement for their effective absorption in the body. 
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Therefore many drug companies are interested more 
to produce bioequivalent   oral drug products. As new 
drug development requires high cost and time,  ma n y  
patents get expired; ease of manufacturing and ready 
availability of technology for the production of oral 
drug products leads many generic pharmaceutical 
companies towards the development   of   
bioequivalent   oral   dosage forms. However, the 
major problem with the design of oral dosage forms 
is their poor  bioavailability.   The   oral 
bioavailability depends on several factors including 
aqueous solubility, drug permeability, dissolution 
rate, first-pass metabolism, pre systemic   
metabolism   and susceptibility   to efflux   
mechanisms
2
 
The usual cause of low oral bioavailability is 
because of p o o r  solubility and low permeability
3
.  
The intensive pharmaceutical research to understand 
the causes of low oral bioavailability have led to the 
development of novel technologies to deal with these 
challenges.  One  of  the  technologies to improve the 
oral bioavailability is  to design a prodrug  with the 
required physico-chemical properties.
4
 For example, 
the prodrug approach resulted in improved 
bioavailability of etilevodopa.
5
 For  BCS class IV 
drugs with poor  solubility  and  poor  membrane 
permeability  and  BCS  class  III  drugs  with high 
solubility and low permeability,  prodrug approach 
is the best option to enhance their bioavailability.  
Though prodrug approach is an interesting way for 
improving the oral bioavailability   of   BCS   class   
II   drugs,   it requires detailed studies to establish the 
safety profile of prodrugs in humans, which 
ultimately may result in failure. Furthermore, the 
main drawback of this approach is the reduced 
solubility of the prodrug.  In today’s market, more 
than 40% of oral drug products contain poorly soluble 
drugs, and among the pharmacopoeia,   this   share   is   
more   than 30%.
6 
For these BCS class II drugs with 
low solubility and reasonable permeability, drug 
dissolution step is the rate-liming process of drug 
absorption.  When administered as oral dosage 
forms, the pharmaceutical formulation plays a critical 
role in the absorption of such drugs from 
gastrointestinal tract. A variety of pharmaceutical 
formulation technologies are used to enhance class II 
drugs. They use already approved excipients and 
GRAS materials. This in turn reduces the cost and 
development time. The common  technologies  
which are used to  achieve  the  enhanced oral 
bioavailability of drugs with poor aqueous solubility 
are  of micronization, nanosizing, crystal engineering, 
solid dispersions, cyclodextrins, solid lipid 
nanoparticles and other colloidal drug delivery 
systems such as microemulsions, self- emulsifying 
drug delivery systems, self microemulsifying   drug  
delivery  systems  and liposomes.
7
 
A brief review of the technologies along with a few 
reports is presented to emphasize their importance in 
enhancing the oral bioavailability of poorly soluble 
drugs. 
METHODS FOR ENHANCEMENT OF THE 
BIOAVAILABILITY 
 As per the definition the drug candidate which has the 
following properties is one with poor bioavailability. 
 Poor  aqueous  solubility and/ or slow 
dissolution rate in the biologic fluids 
 Poor stability  of the dissolved  drug at the 
physiologic pH 
 Inadequate  partition coefficient and thus poor 
permeation through the biological membrane 
 Extensive presystemic metabolism 
There   are   three   major   approaches used to 
overcome the bioavailability problems. 
A) Pharmaceutics approach: 
It is done by modifying of formulation, manufacturing 
processes or physiochemical properties of the drug 
are done. 
B) Pharmacokinetic approach: 
Alteration of pharmacokinetic parameters by 
modifying its chemical structure. 
C) Biological approach: 
The route of administration is changed in this method. 
Solubility and rate of dissolution are very important 
factors in third approach. 
Co-solvency 
The solubility of a poorly water soluble drug can 
be increased by the addition of a  water  miscible  
solvent  in  which  the  drug has good solubility 
known as cosolvents
.8
Co-solvents are mixtures of 
water and one or more water miscible solvents used to 
prepare a solution with enhanced solubility for poorly 
soluble compounds. This is one of the most widely 
used techniques because of its simplicity. 
Cosolvents can be easily produced and evaluated. 
Examples of solvents used in co-solvent mixtures are 
PEG 300, propylene glycol or ethanol. Co-solvent 
formulations of poorly soluble drugs can be 
administered orally and parentally.
 
Amit et al examined and compared the cosolvency 
using three different cosolvents which are PEG 400, 
PG, and glycerin on the aqueous solubility 
enhancement of a poorly aqueous soluble drug, 
etoricoxib, since solubilization of nonpolar drugs 
constitutes one of the important tasks in the 
formulation design of liquid dosage forms. The 
aqueous solubility of etoricoxib was 
0.0767±0.0018 mg/mL, which was significantly 
enhanced by the addition of PEG 400, PG, and 
glycerin as cosolvents. It was analysed that the less-
polar solvents increased the aqueous solubility by 
greater extent, thus emphasizing hydrophobic 
interaction mechanism. Among various solvent-
cosolvent mixtures investigated, water-PEG 400 
showed highest solubilization potential. Thus, the 
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study generated an important pattern of data to 
compare the effect of these cosolvents on the aqueous 
solubility of etoricoxib.
9 
Particle size reduction 
The bioavailability is also related to drug particle 
size. By reducing particle size,surface area increases 
which in turn  improves the dissolution properties. 
Particle size reduction is done by milling techniques 
using jet mill, rotor stator colloid mills etc. Size 
reduction is not suitable for drugs having a high dose 
number because it does not change the saturation 
solubility of the drug. 
Currently Particle size reduction can also be achieved 
by micronisation and nanosuspension. Each technique 
utilizes different   equipments   for   reduction   of   
the particle size. In micronization the solubility of 
drug i s  o f t e n  i n t r i n s i c a l l y    related   to 
d r u g  particle size. By reducing particle size,surface 
area increases which in turn  improves the 
dissolution properties. Micronization of drugs is done 
by milling techniques using jet mill, rotor stator 
colloid mills etc.  Micronization i s  not suitable for 
drugs having a high dose number because it does not 
change the saturation solubility of the drug. 
Bansal et al studied that the dissolution rate is one of 
the limiting factors for achieving good bioavailability. 
In various formulations, the particle size of drugs and 
components may affect the processing and 
bioavailability. Many compounds that are investigated 
in pharmaceutical field have low aqueous solubility 
and fall in class II and IV of the biopharmaceutical 
classification system. Particle size reduction, leading 
to increase in surface area, is a leading tool to increase 
dissolution rate and in turn the bioavailability of poor 
water soluble compound  
In this work it was attempted to improve dissolution 
profile of Norethindrone from the tablet dosage form 
by using micronization techniques to decrease particle 
size. Particle size reduction was achieved by Air Jet 
Milling. Micronization of Norethindrone caused 
enhancement in the dissolution rate to a significant 
extent when compared with unmicronized material. 
Norethindrone Oral Tablets which are commercially 
available in Indian market showed similar dissolution 
property as the tablets prepared with unmicronized 
Norethindrone, while those prepared with micronized 
Norethindrone showed higher dissolution rate. The 
result suggest that micronization technique can be used 
for the preparation of rapidly dissolving formulations 
of Norethindrone, and could potentially lead to 
improvement in the in vivo bioavailability of oral 
Norethindrone Tablets.
10
 
Hydrotrophy 
Currently number of techniques addressed the 
enhancement of solubility and dissolution rate of 
poorly soluble drugs. Hydrotropic solubilization is one 
of them.  
Hydrotrophy  is  a  solubilisation  technique in which  
a large amount of second solute  is added which 
results  in  an increase  in  the  aqueous solubility of 
another solute. Solute which is used consists of alkali 
metal salts of various organic acids. A hydrotrope is a 
compound that solubilises hydrophobic compounds in 
aqueous solution Hydrotropes are having the ability to 
increase the solubility of poorly water soluble drug and 
this tendency is greatest when concentration of 
hydrotropes is sufficiently enough to form the 
associated structures. 
11
.  
Hydrotropic agents are ionic organic salts. The 
additives  or  salts  that  increase  solubility  in given 
solvent are said to “salt in” the solute and those  salts  
that  decrease  solubility  “salt  out” the solute. 
Several  salts with large anions  or cations  that  are  
themselves  very  soluble  in water result  in “salting  
in” of non electrolytes called “hydrotropic salts” a 
phenomenon known as  “hydrotropism”
12
 
Hydrotropic  solutions  do not  exhibit  colloidal  
properties  and  involve  a weak interaction between 
the hydrotropic agent and solute. Hydrotrophy leads 
to increase in solubility in water due to the presence 
of large amount of additives. The mechanism by 
which it improves solubility is more closely related   
to   complexation   involving   a   weak interaction 
between the hydrotrophic agents like sodium 
benzoate, sodium acetate, sodium alginate, urea 
and the poorly soluble drugs.
13,14
 
Maheshwari et al in their study employed hydrotropic 
solution of ibuprofen sodium (0.5M)  as solubilizing 
agent to solubilize the poorly water-soluble drug, 
ornidazole from fine powder of its tablets for 
spectrophotometric determination. Ornidazole shows 
its maximum absorbance at 320 nm and Beer’s law 
was obeyed in concentration range of 5-25mcg/ml.
15
 
Mixed Hydrotropy  
It is a solubilization technique to increase the water 
solubility of poorly water soluble drugs by using 
different ratio of blends of hydrotropic agents which 
gives synergistic enhancement effect. The main 
advantage of this technique is that it reduces the 
concentration of individual hydrotropic agents which 
directly reduces the side effects of individual 
hydrotropic agent. A novel, safe and sensitive method 
of spectrophotometric determination of 
Hydrochlorothiazide in tablets was developed using 
mixed hydrotropic solubilisation technique and 
concluded that there is enhancement of solubility up to 
25 folds by mixed hydrotropy. Hydrotropic solid 
dispersion of aceclofenac was formulated and 
evaluated by using six blends of hydrotropes (urea and 
sodium citrate) and concluded that solubility of 
aceclofenac increases synergistically by mixed 
hydrotropic solublization technique.
16
 A further study 
was analyzed by using mixed hydrotropy on 
nitazoxanide, using sodium benzoate and sodium 
salicylate as hydrotropic agents and accomplished that 
there is enhancement of solubility up to 12 folds.
17
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Solid dispersions 
The   effective   surface   area   is   one   of   the 
important factors which govern the dissolution rate of 
poorly soluble drugs. Apart from micronization and 
nanosizing technologies, solid dispersion is the other 
way of enhancing t h e  effective surface area 
available for dissolution.
18,19 
The term solid dispersion refers to a group of solid 
products consisting of at least two different 
components, generally a hydrophilic matrix(carrier) 
and a hydrophobic drug. The matrix can be either 
crystalline or amorphous. As per biopharmaceutical 
classification system class II drugs are with low 
solubility and high permeability and are the 
promising candidates for improvement of 
bioavailability by solid dispersion
20
.  
A carrier should meet the following criteria to be 
suitable for increasing the dissolution rate of a drug.
21
  
 Freely water-soluble with intrinsic rapid 
dissolution properties.  
 Non-toxic and pharmacologically inert.  
 Heat stable with a low melting point for the melt 
method.  
 Soluble in a variety of solvents and pass through a 
vitreous state upon solvent evaporation for the 
solvent method.  
 Able to preferably increase the aqueous solubility 
of the drug.  
Solid dispersions increase the dissolution rate of 
poorly water soluble drugs by one of the following 
mechanisms
22
 .  
 Reduction in particle size  
 Improvement in wettability and dispersibility  
 Changing crystalline form of drug to amorphous 
form  
 Reduction in aggregation and agglomeration of drug 
particles. 
These are usually prepared by heating a mixture of 
the drug and carrier to a molten state, and then 
cooled for resolidification. A solid dispersion of 
nitrendipine prepared by a melt-mixing method in 
which silica particles were used as carriers showed 
remarkably improved dissolution properties 
compared with that of the original nitrendipine 
crystals.
23
 
In an another  study by, Ha et al, solid dispersion 
nanoparticles with a hydrophilic polymer and 
surfactant were developed using the supercritical 
antisolvent (SAS) process to improve the dissolution 
and oral absorption of megestrol acetate. The physical 
and chemical properties of the megestrol acetate solid 
dispersion nanoparticles were studied using scanning 
electron microscopy, differential scanning calorimetry, 
powder X-ray diffraction, and particle-size analyzer. 
The oral bioavailability and dissolution of the 
nanoparticles were also studied in rats. 
Hydroxypropylmethyl cellulose solid dispersion 
nanoparticles significantly increased the maximum 
dissolution when compared with polyvinylpyrrolidone 
K30 solid dispersion nanoparticles. The dissolution 
rate along with extent of megestrol acetate increased 
after the adding a surfactant into the HPMC solid 
dispersion nanoparticles. The most effective surfactant 
was Ryoto sugar ester L1695, followed by d-a-
tocopheryl polyethylene glycol 1000 succinate. The 
results suggested that the preparation of megestrol 
acetate solid dispersion nanoparticles using the 
supercritical antisolvent process is a promising 
approach to improve the dissolution and bioavailability 
of megestrol acetate.
24 
The major disadvantages of solid dispersion are related 
to their instability. Several systems have shown 
changes in crystallinity and a decrease in dissolution 
rate with aging. The crystallization of ritonavir from 
the supersaturated solution in a solid dispersion system 
was responsible for the withdrawal of the ritonavir 
capsule (Norvir, \Abboft) from the market
25
.
 
Micellar solubulisation 
Various surfactants can also be employed   to improve 
the dissolution performance of poorly soluble drug 
products. Surfactants  lower surface tension and 
improve  the  dissolution  of  lipophilic  drugs  in 
aqueous medium.
26,27,28 
They are also used to 
stabilise drug suspensions. When the concentration   
of   surfactants   exceeds   their critical micelle 
concentration (CMC, which is in the range of 0.05-
0.10% for most surfactants), micelle formation 
occurs, thus entrapping the drugs within the 
micelles.
29
 This process is called as micellisation and 
causes enhancement of solubility of poorly soluble 
drugs. Commonly used non-ionic surfactants 
include polysorbates,   polyoxy   ethylated   castor   
oil, polyoxyethylated glycerides, lauroyl 
macroglycerides and mono- and di-fatty acid esters of 
low molecular weight polyethylene glycols. 
Surfactants are also often used to stabilize 
microemulsions  and suspensions into which drugs 
are dissolved.
30 
Micellar  solubilisation  is  a  widely  
used alternative for the dissolution of poorly soluble 
drugs.
31 
Examples of  poorly soluble compounds that 
use Micellar solubilisation are antidiabetic drugs,  
gliclazide,  glyburide,  glimepiride, glipizide, 
repaglinide, pioglitazone androsiglitazone.
32 
Meenakshi et al studied solubility studies of Glipizide 
using different solubilization techniques. 
Different concentration (0.2. 0.4, 0.6, 0.8, 1.0 % w/v) o
f   surfactants (Sodium lauryl sulphate, cetrimide and t
ween 80were prepared.An excess of glipizide was add
ed to 10 mL each of the surfactant solution taken in 25 
mL of stopperedflasks. The flasks were shaken for 24 
h. At equilibrium samples were withdrawn and properl
y diluted and filtered through filter of pore size of 0.22
 mm and analyzed for concentration of glipizide spectr
ophotometrically at 274 nm.The study also evaluated a
nd compared solubility enhancement of glipizide using 
three different surfactants glipizide using three 
different surfactants i.e. sodium lauryl sulphate 
Khan et al                                         Journal of Drug Delivery & Therapeutics. 2016; 6(3):34-41 38 
© 2011-15, JDDT. All Rights Reserved                                    ISSN: 2250-1177                                 CODEN (USA): JDDTAO 
Tween 80 and cetrimide. Tween 80 was found to be 
the most efficient surface active agent, improving 
solubility by nearly to 36 folds. Thus from this compar
ative 
solubility analysis of glipizide using different solubiliz
ation techniques can further be successfully applied for
 development and formulation of liquid or semisolid d
osage form of glipizide.
33
 
Complexation  
 There are various approaches of complexation with 
cyclodextrins which have gained good acceptance in 
recent years in industry for enhancing the solubility 
and  thus dissolution rate of poorly soluble drugs. 
Cyclodextrins (CDs) are cyclic torus-shaped molecules 
with a hydrophilic external surface and lipophilic 
central cavity which can accommodate a variety of 
lipophilic drugs. As a result of inclusion process, many 
physicochemical properties such as solubility, 
dissolution rate, stability and bioavailability can be 
effectively enhanced. Cyclodextrins are being 
increasingly applied in various pharmaceutical 
formulations in recent years. Cyclodextrins are 
produced from starch by means of enzymatic 
conversion. 
34,35 
CDs are capable of forming inclusion complexes with 
many drugs by taking up a whole drug molecule, or 
some part of it, into the cavity. Such molecular 
encapsulation will affect many of the physicochemical 
properties of drugs, mainly their aqueous solubility 
and rate of dissolution. Among the various approaches, 
preparation of inclusion complexes with cyclodextrin 
have found to be successful in enhancing the solubility 
of poorly water soluble drugs.
36,37,38
 Among the three 
types of CDs β - Cyclodextrin is known to be more 
suitable for practical use because of the following 
three reasons.
38,39,40,41 
Solubilizing excipients 
Surfactants have also been successfully employed to 
improve the dissolution   performance   of   poorly   
soluble drug products.  Surfactants lower the surface 
tension and increase the solubility   of   the   drug   
within   an   organic solvent. Surfactants are also used 
to improve the stability microemulsions   and   
suspensions into which drugs are dissolved. The 
presence of  surfactants may found incompatible 
within  a  drug  product formulation  with  drug  
delivery  technologies  which  are based  upon   well-
regulated   hydration,   dissolution and matrix  
erosion or coating to achieve controlled release. The 
influence of the changes in pH in the gastrointestinal 
tract upon the bioavailability of pharmaceuticals is 
well documented.  
The absorption largely dependent upon diffusion, 
which  changes with the pKa of the drug and the pH of 
the individual  regions  within  the  gastrointestinal 
tract, and permeability, which is not only altered by 
the surface area of the region in which it is released,  
but also the regional pH effects when drug ionizes  
.While the importance of salt used and pH adjustment 
has  been  stressed  as  an  i m p o r t a n t   parameter  
of pre-formulation,  the  use  of  pH-altering 
excipients within drug delivery systems is also of 
great importance. Solubilised excipients that increase 
environmental p H  in a dosage form, such as a tablet 
or capsule, to a range above that of p K a  of weakly-
acidic drugs increases the solubility of that drug. 
Excipients which act as alkalising agents may increase 
the solubility of weakly basic drugs. Another example 
is a use of pH-inducing excipients is SCOLR Inc’s 
self-correcting hydrogel systems.  One  or  more  
electrolytes are  included  within  the  dosage  form  
whose pKa  is  complementary  to  the  drug;  after the 
hydration of dosage form  , the electrolyte is wetted 
simultaneously with the active compound, creating a 
microenvironment independent of gastrointestinal   
pH.   Micro environmental    pH may be changed  to  
enhance  dissolution  of poorly   soluble   drugs   by   
salting-in effects through the inclusion of electrolytes 
of different hydrophobic  character;  oppositely,  intra- 
dosage form pH may induce precipitation of highly  
soluble drugs, thereby decreasing the rate of  
dissolution through salting-out effects. 
Colloidal drug delivery systems 
The formulations containing lipids  have been shown 
to enhance the bioavailability of orally administered 
drugs.
42,43,44,45
 .As lipidic excipients are widely 
available with specific characteristics  they offer  
various applications with respect to improve the 
bioavailability of poorly water-soluble drugs and 
changing their release profiles .
46
  
Self-microemulsifying drug delivery systems 
(SMEDDS) are a promising approach for the 
formulation of drug compounds with poor aqueous 
solubility. The oral delivery of hydrophobic drugs can 
be made possible by SMEDDSs, which have been 
shown to substantially improve oral bioavailability and 
thus the dose of the drug can be reduced. 
47
. 
Self micro emulsifying drug delivery system 
(SMEDDS) are  as isotropic mixtures of natural or 
synthetic oils, solid or liquid surfactants, or 
alternatively, one or more hydrophilic solvents and co-
solvents/surfactants that have a unique ability of 
forming fine oil-in-water (o/w) micro emulsions by 
agitating mildly followed by diluting in an aqueous 
media, such as GI fluids.
48
 SMEDDS are advanced as 
compared to the other drug delivery systems due to 
their ability to deliver various macromolecules like 
peptides, hormones, enzyme substrates and inhibitors 
and protect them from enzymatic hydrolysis. The 
intestinal hydrolysis of prodrug by cholinesterase can 
be protected if Polysorbate 20 is emulsifier in micro 
emulsion formulation.
49
 These systems are formed 
spontaneously without aid of energy or heating thus 
suitable for thermolabile drugs such as peptides. 
SMEDDS are generally prepared as liquid dosage 
forms that can be administrated as soft gelatin 
capsules, which have some disadvantages especially in 
the manufacturing process. An alternative method is 
the incorporation of liquid self emulsifying ingredients 
into a powder in order to create a solid dosage form 
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(tablets, capsules).  Pellets of progesterone in 
SMEDDS have been prepared by the extrusion 
spheronization process to provide a better in vitro drug 
release .The similar dose of progesterone (16 mg) in 
pellets and in the SEDDS liquid formulation resulted 
in similar AUC, C max and T max values.
50 
With future development of this technology, 
SMEDDSs will continue to enable novel applications 
in drug delivery and solve problems associated with 
the delivery of poorly soluble drugs 
However, conventional SMEDDS are mostly prepared 
in a liquid form, which can have some disadvantages. 
Hence, solid SMEDDS (S-SMEDDS) prepared by 
solidification of liquid/semisolid self-micron 
emulsifying ingredients into powders, have gained 
popularity 
51
 
The nanosuspensions technology can be successfully 
utilized for overcoming problems associated with 
poorly soluble drugs or lipophilic drugs insoluble in 
both organic and aqueous media
52
. To enhance the 
bioavailability of curcumin different formulations have 
been made. Among them, nanoglobules based 
nanoemulsion formulation has been prepared to 
evaluate the potential for the solubility enhancement of 
curcumin. During ex vivo study, the release of 
curcumin from nanoemulsion was found much higher 
than curcumin suspension. This showed the increase in 
solubility of curcumin in aqueous solution.
53
Another 
study showed that encapsulating the curcumin into the 
hydrogel nanoparticles yielded homogenous curcumin 
dispersion in aqueous solution compared to the free 
form of curcumin. The in vitro release profile showed 
up to 95% release of curcumin from the developed 
nano-microparticulate systems.
54 
Akhgari et al prepared a nanosuspension formulation 
as a new vehicle for the improvement of the ocular 
delivery of vitamin A. Formulations were designed 
based on full factorial design. High pressure 
homogenization technique was employed to produce 
nanosuspensions. Fifteen formulations were prepared 
by using different combinations of surfactants Tween 
80, benzalkonium chloride and Pluronic and evaluated 
for pH, particle size, entrapment efficiency, 
Differential scanning calorimetry (DSC), stability and 
drug release. Also, Draize test was used to evaluate the 
irritation of rabbit eye by formulations. All 
formulations showed a small mean size that is well 
suited for ocular application. Also it was observed that 
the particle size decreased with increase in the amount 
of surfactant. Drug entrapment increased with 
increasing amount of surfactant. It was shown that 
initial and final drug release can be controlled by the 
ratio and the total amount of surfactants, respectively. 
It was found that the use of Tween 80 and Pluronic in 
the formulations with a proper ratio does not show eye 
irritation and could be useful to prepare a suitable 
nanosuspension of vitamin A as a novel ocular deliver 
system.
55
 
Liquisolid Technique 
Liquisolid technique is also known as powder solution 
technology. Liquisolid is mainly composed of drug, 
non volatile solvent, carrier material, coating material, 
and disintegrant.
56
 In liquisolid technique carrier and 
coating material which should be in the ratio of 20:1 is 
mixed into the non volatile solvent and then 
disintegrant is added and final material is compressed 
into tablets. Hence, the liquisolid technology allows 
the transformation of liquid systems into solid drug 
delivery systems. Both immediate and sustained 
release of drug can also be achieved with the help of 
liquisolid technique. For sustained release of drug 
hydrophilic polymer like Hydroxy Propyl Methyl 
Cellulose can be the best option.
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Classification of liquisolid systems 
Based on the type of liquid medication contained 
therein, liquisolid systems may be classified into three 
sub-groups. 
1) Powdered drug solutions 
2) Powdered drug suspensions 
3) Powdered liquid drugs 
Powdered drug solutions and suspensions may be 
produced from the conversion of drug solutions or 
drug suspensions into liquisolid systems and powdered 
liquid drugs are produced from the formulation of 
liquid drugs into liquisolid systems. 
         
Figure 1: Steps of Liquisolid Technique
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Drug+ non volatile 
solvent  
Hot medication is added 
into  carrier and coating 
material 
This mixture is  
continously mixed in a 
motar 
Mixing process is carried 
out in three steps 
Step 1: Mixture is rotated for 1 
rotation per second for one minute 
for complete mixing of liquid 
medication in powder 
Step 2: This mixture is spread over 
the motar for 5 minute so that drug 
get absorbe in the intrior  of 
powder  
Step 3: Powder is 
scraped off  
Disintegrant is added 
and left for 10-20 
minutes 
Other additive are 
added and the  
punched into tablets. 
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Simultaneously, based on the formulation technique 
used, liquisolid systems may be classified into two 
categories namely, 
1) Liquisolid compacts 
2) Liquisolid microsystems 
The term “liquisolid compacts” refers to immediate or 
sustained release tablets or capsules prepared and 
combined with the inclusion of appropriate adjuvant 
required for tabletting or encapsulation, such as 
lubricants, and for rapid or sustained release action, 
such as disintegrants or binders. 
The term “liquisolid Microsystems” refers to capsules 
prepared by combining the drug with carrier and 
coating materials with inclusion of an additive e.g., 
PVP in the liquid medication wherein the resulting unit 
size may be as much as five times that of liquisolid 
compacts.
58 
Co-crystalization: 
Co-crystals are known as crystalline complexes of two 
or more neutral molecular constituents, bound together 
in crystal lattice through non covalent interaction. Co-
crystals can be prepared with several methods such as 
solution evaporation, solid grinding, and solvent drop 
grinding and sonocrystallization method. The 
pharmaceutical co crystal are prepared by combination 
of API and coformer i.e. pharmaceutically acceptable 
molecule inside a crystal lattice. As a matter of fact co-
crystals increase the diversity of API form. Co-
crystallization is molecular association of similar or 
different molecules, the network of hydrogen bonds 
results in generation of families in the molecular 
network. 
Co-crystallization involves alteration in molecular 
assemblies and composition of pharmaceutical 
substance and which ultimately results in enhancing 
physical properties. Cocrystals are molecular complex 
brings about changes in solubility, bioavailability and 
stability in pharmaceutical designing without 
interacting with therapeutic utility. The major factor 
which affects cocrystal preparation is its 
thermodynamic stability. As concern with the 
therapeutic utility, cocrystals will play major role in 
development of formulation
59
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